Literature DB >> 18931888

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review.

Mahdi Aghili1, Fatemeh Zahedi, Elham Rafiee.   

Abstract

L -2-Hydroxyglutaric aciduria (L -2-OHGA) is a rare autosomal recessive inherited encephalopathy. This inborn error, characterized by psychomotor retardation, progressive ataxia and typical magnetic resonance imaging findings, presents in early infancy. To make a definitive diagnosis, an anomalous accumulation of L -2-hydroxyglutaric acid must be detected in body fluids. Here, we present a 17-year-old boy with L: -2-OHGA who developed an anaplastic ependymoma during the course of this disease. We also present a literature review including seven other patients who developed malignant brain tumors during the course of L -2-OHGA. This correlation may indicate a possible increased risk of brain tumors among patients with L -2-hydroxyglutaric aciduria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931888     DOI: 10.1007/s11060-008-9706-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  14 in total

1.  Spinal canal stenosis in L-2-hydroxyglutaric aciduria.

Authors:  M Warmuth-Metz; G Becker; M Bendszus; L Solymosi
Journal:  Arch Neurol       Date:  2000-11

2.  Clinical, biochemical and neuroradiological findings in L-2-hydroxyglutaric aciduria.

Authors:  I Moroni; L D'Incerti; L Farina; M Rimoldi; G Uziel
Journal:  Neurol Sci       Date:  2000-04       Impact factor: 3.307

3.  L-2-hydroxyglutaric acidemia: a novel inherited neurometabolic disease.

Authors:  P G Barth; G F Hoffmann; J Jaeken; W Lehnert; F Hanefeld; A H van Gennip; M Duran; J Valk; R B Schutgens; F K Trefz
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

4.  L-2-Hydroxyglutaric aciduria: MRI in seven cases.

Authors:  L D'Incerti; L Farina; I Moroni; G Uziel; M Savoiardo
Journal:  Neuroradiology       Date:  1998-11       Impact factor: 2.804

5.  L-2-hydroxyglutaric aciduria: three Australian cases.

Authors:  B Wilcken; J Pitt; D Heath; P Walsh; G Wilson; N Buchanan
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells.

Authors:  M Theodoropoulou; T Arzberger; Y Gruebler; M L Jaffrain-Rea; J Schlegel; L Schaaf; E Petrangeli; M Losa; G K Stalla; U Pagotto
Journal:  J Endocrinol       Date:  2004-11       Impact factor: 4.286

7.  L-2-Hydroxyglutaric aciduria: neuropathological correlations and first report of severe neurodegenerative disease and neonatal death.

Authors:  E Chen; W L Nyhan; C Jakobs; C M Greco; A J Barkovich; V A Cox; S Packman
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

8.  Molecular analysis of astrocytoma associated with Turcot syndrome type 1--case report.

Authors:  Hiroaki Okamoto; Toshihiro Mineta; Yukiko Nakahara; Makoto Ichinose; Tetsuya Shiraishi; Kazuo Tabuchi
Journal:  Neurol Med Chir (Tokyo)       Date:  2004-03       Impact factor: 1.742

9.  L-2-Hydroxyglutaric aciduria: an inborn error of metabolism?

Authors:  M Duran; J P Kamerling; H D Bakker; A H van Gennip; S K Wadman
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

10.  PDGF and FGF2 regulate oligodendrocyte progenitor responses to demyelination.

Authors:  Emma E Frost; Joseph A Nielsen; Tuan Q Le; Regina C Armstrong
Journal:  J Neurobiol       Date:  2003-02-15
View more
  61 in total

Review 1.  The redox basis of epigenetic modifications: from mechanisms to functional consequences.

Authors:  Anthony R Cyr; Frederick E Domann
Journal:  Antioxid Redox Signal       Date:  2011-02-05       Impact factor: 8.401

Review 2.  Alterations of metabolic genes and metabolites in cancer.

Authors:  Eric K Oermann; Jing Wu; Kun-Liang Guan; Yue Xiong
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

3.  IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma.

Authors:  Ying Liu; Wenqing Jiang; Jing Liu; Shimin Zhao; Ji Xiong; Ying Mao; Yin Wang
Journal:  J Neurooncol       Date:  2012-07-08       Impact factor: 4.130

4.  Preface to the column "Metabolism of Childhood Cancer".

Authors:  Dinesh Rakheja
Journal:  Transl Pediatr       Date:  2015-01

Review 5.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

6.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

Authors:  Meghan J Seltzer; Bryson D Bennett; Avadhut D Joshi; Ping Gao; Ajit G Thomas; Dana V Ferraris; Takashi Tsukamoto; Camilo J Rojas; Barbara S Slusher; Joshua D Rabinowitz; Chi V Dang; Gregory J Riggins
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

7.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.

Authors:  Whitney B Pope; Robert M Prins; M Albert Thomas; Rajakumar Nagarajan; Katharine E Yen; Mark A Bittinger; Noriko Salamon; Arthur P Chou; William H Yong; Horacio Soto; Neil Wilson; Edward Driggers; Hyun G Jang; Shinsan M Su; David P Schenkein; Albert Lai; Timothy F Cloughesy; Harley I Kornblum; Hong Wu; Valeria R Fantin; Linda M Liau
Journal:  J Neurooncol       Date:  2011-10-21       Impact factor: 4.130

Review 8.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

9.  IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?

Authors:  Marianne Labussiere; Marc Sanson; Ahmed Idbaih; Jean-Yves Delattre
Journal:  Oncologist       Date:  2010-02-04

10.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.